» Articles » PMID: 37153060

Molecular Subtyping in Colorectal Cancer: A Bridge to Personalized Therapy (Review)

Overview
Journal Oncol Lett
Specialty Oncology
Date 2023 May 8
PMID 37153060
Authors
Affiliations
Soon will be listed here.
Abstract

Colorectal cancer (CRC) is a malignant tumor and a major cause of morbidity and mortality globally. The classic Tumor-Node-Metastasis staging system, which currently underlies the diagnosis and treatment of CRC, is primarily a 'one drug fits all' model for patients exhibiting the same pathological features. However, a high degree of variability has been established in the long-term survival outcomes of patients with CRC with similar pathological types and stages, which can be partially attributed to tumor-specific molecular biology to some extent. Molecular classification of CRC can further assist with understanding the biological behavior of tumor genesis, development and prognosis, and assist clinicians in improving or customizing the treatment strategy of CRC. In the present study, clinical studies carried out to date are reviewed, and their clinical value is discussed. A multilevel overview of the major molecular types of CRC is provided, in the hope that investigators are encouraged to combine multiple omics studies for interrogating cancer.

Citing Articles

Advances in Precision Medicine Approaches for Colorectal Cancer: From Molecular Profiling to Targeted Therapies.

Kiran N, Yashaswini C, Maheshwari R, Bhattacharya S, Prajapati B ACS Pharmacol Transl Sci. 2024; 7(4):967-990.

PMID: 38633600 PMC: 11019743. DOI: 10.1021/acsptsci.4c00008.


JAML inhibits colorectal carcinogenesis by modulating the tumor immune microenvironment.

Cheng S, Li M, Li C, Dai Y, Zhuo J, Wang J In Vitro Cell Dev Biol Anim. 2024; 60(4):382-396.

PMID: 38625487 DOI: 10.1007/s11626-024-00881-8.


Comparison of Microsatellite Instability With Clinicopathologic Data in Patients With Colon Adenocarcinoma.

Cesmecioglu Karavin E, Yilmaz Z, Yazici H, Ersoz S, Mungan S Cureus. 2024; 16(4):e57814.

PMID: 38590982 PMC: 11000436. DOI: 10.7759/cureus.57814.


A comparative study of clustering methods on gene expression data for lung cancer prognosis.

Zhang J, Wang C BMC Res Notes. 2023; 16(1):319.

PMID: 37941025 PMC: 10630994. DOI: 10.1186/s13104-023-06604-8.


Transcriptome and proteome analysis reveals the anti-cancer properties of Hypnea musciformis marine macroalga extract in liver and intestinal cancer cells.

Begolli R, Chatziangelou M, Samiotaki M, Goutas A, Barda S, Goutzourelas N Hum Genomics. 2023; 17(1):71.

PMID: 37525271 PMC: 10388463. DOI: 10.1186/s40246-023-00517-0.

References
1.
Venderbosch S, Nagtegaal I, Maughan T, Smith C, Cheadle J, Fisher D . Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014; 20(20):5322-30. PMC: 4201568. DOI: 10.1158/1078-0432.CCR-14-0332. View

2.
Swanton C, Tomlinson I, Downward J . Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle. 2006; 5(8):818-23. DOI: 10.4161/cc.5.8.2682. View

3.
Zeng W, Liu G, Xu J, Zhou X, Zhang Y, Zhang N . Pathological characteristics, PCNA labeling index and DNA index in prognostic evaluation of patients with moderately differentiated hepatocellular carcinoma. World J Gastroenterol. 2002; 8(6):1040-4. PMC: 4656376. DOI: 10.3748/wjg.v8.i6.1040. View

4.
Pazdur R, Lassere Y, Soh L, Ajani J, Bready B, Soo E . Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma. Ann Oncol. 1994; 5(5):468-70. DOI: 10.1093/oxfordjournals.annonc.a058883. View

5.
Issa J . CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004; 4(12):988-93. DOI: 10.1038/nrc1507. View